About Intarcia Therapeutics
Intarcia Therapeutics was founded around 2007, based in Hayward, California with later leadership based in Boston, developing a novel drug-device combination product for type 2 diabetes called ITCA 650, built around the company's proprietary Medici/DUROS delivery system, a matchstick-sized osmotic pump implanted just under a patient's skin that continuously releases a steady, low dose of exenatide, an injectable GLP-1 diabetes medication, over a period of three to six months, an approach the company argued could improve patient convenience and treatment adherence relative to the frequent self-injections that GLP-1 diabetes and, later, weight-loss drugs typically require. The concept attracted enormous investor enthusiasm, and Intarcia raised more than $1 billion in venture funding across several very large rounds, at one point valued near $3.5 billion, with backers including the Bill & Melinda Gates Foundation, which was separately interested in the underlying implant technology's potential to deliver long-acting HIV prevention medication.
Intarcia's fortunes collapsed after its diabetes implant was rejected twice by the U.S. Food and Drug Administration, first in 2017 citing manufacturing quality concerns and safety signals including acute kidney injury observed in some trial patients, and again in 2020 after a resubmission. Unable to secure approval or additional financing after these setbacks, Intarcia conducted significant layoffs, closed its Hayward manufacturing facility, and filed for Chapter 11 bankruptcy in late 2020, liquidating its physical lab and office assets through an auction, in what was described as one of the largest biotech bankruptcies in Boston's history. In August 2023, a Boston-based startup called i2o Therapeutics, backed by investors including Sanofi Ventures, acquired Intarcia's remaining ITCA 650 program and underlying delivery-system intellectual property out of the bankruptcy, and Intarcia's former CEO Kurt Graves became i2o's executive chairman. Development continued for a time under i2o, but in September 2023 an FDA advisory committee unanimously voted against the implant a third time, again citing safety concerns including kidney injury risk, and in August 2024 the FDA issued a final refusal to approve the product, concluding its unresolved safety risks outweighed its benefits, closing out a cautionary case study in how a single make-or-break regulatory decision can determine the fate of an enormously well-funded biotech venture.
